Inventor
Peng-cheng LU
Inventor
US
Overview
Patents· 7 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes29%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations29%
C07DHeterocyclic compounds29%
C07BGeneral methods of organic chemistry8%
C07CAcyclic or carbocyclic compounds4%
PatentTitleYear
12,558,341Oral complement factor D inhibitors202612,054,492Imidazole-containing inhibitors of ALK2 kinase202412,043,610Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors202411,866,418Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors202411,708,347Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors202311,661,426Imidazole-containing inhibitors of ALK2 kinase202311,370,774Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2026Patents assigned to BIOCRYST PHARM INC (7)· patent assignee history
2022–2026Based in US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| BIOCRYST PHARM INC | 7 | 2022–2026 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 7 | 2022–2026 |